B
acillus anthracis, the etiological agent of anthrax, infects mammals (1) . Upon entry into the host, the spore, the infective form of B. anthracis, germinates and gives rise to the vegetative form that produces the virulence factors, mainly the edema and lethal toxins and the capsule. Expression of these factors leads to anthrax, an association of toxemia and rapidly spreading infection evolving into septicemia with a fatal outcome in the absence of treatment. Some animal species are relatively resistant to anthrax infection. This trait has been correlated to the extent of the local inflammatory reaction (2) , suggesting the occurrence of natural mechanisms controlling B. anthracis infection. Anthrax is an acute disease; therefore, innate immunity is the first line of defense that may act at an early stage of B. anthracis infection in nonimmunized hosts. However, little is known about the innate immune response that is triggered upon infection by B. anthracis spores. In a previous study, we showed that group IIA secreted phospholipase A 2 (sPLA 2 -IIA) 5 is bactericidal in vitro and ex vivo for B. anthracis as soon as it germinates and at the capsulated bacillus stage (3) .
sPLA 2 -IIA belongs to a family of enzymes that catalyze the hydrolysis of phospholipids at the sn-2 position, leading to the generation of lysophospholipids and free fatty acids, especially arachidonic acid (4) . These products are converted into a variety of lipid mediators such as platelet-activating factor and eicosanoids, which play a major role in the initiation and modulation of inflammation (5) . This production of lipid mediators is an integral component of the inflammatory reaction and might indirectly contribute to the host defense against invading pathogens. However, sPLA 2 -IIA plays a more direct role in the host defense reaction against bacteria; sPLA 2 -IIA is produced in particular by macrophages, which seems a major source of this enzyme in vivo (6, 7) and possesses potent antibacterial activity, especially toward Gram-positive bacteria (6, 8 -10) . The bactericidal activity always involves the hydrolysis of the phospholipids in bacterial membranes (6) . The protective role of sPLA 2 -IIA against bacterial infections was highlighted previously in sPLA 2 -IIA Ϫ/Ϫ mice (11) and transgenic mice expressing human sPLA 2 -IIA (12). The absence of sPLA 2 -IIA affects the anti-bacterial response to Staphylococcus aureus infection, leading to a higher death rate compared with mice overexpressing sPLA 2 -IIA. Transgenic sPLA 2 -IIA mice are resistant to experimental infection with S. aureus and Escherichia coli (11, 13, 14) . Such resistance was not correlated to a modified inflammatory status; in the steady state, sPLA 2 -IIA transgenic mice do not present any evidence of inflammation in the skin, liver, lung, spleen, pancreas, or thymus (12) . Moreover, despite enhanced basal expression of sPLA 2 -IIA in these transgenic mice and in two other transgenic mouse models expressing sPLA 2 -IIA under inducible or specific promoters (15, 16) , no evidence of an overt inflammatory status has been observed. In this latter model, in which sPLA 2 -IIA was overexpressed in macrophages, T cell lineages, smooth muscle cells, and fibroblasts were not significantly affected in the atherosclerotic lesions induced by high-fat diet, nor was any change in inflammatory cells observed (16) .
As we had previously shown that B. anthracis is killed by sPLA 2 -IIA in vitro and ex vivo (3), we undertook the present study to investigate the role of sPLA 2 -IIA in vivo in the control of B. anthracis infection. The resistance of transgenic mice expressing human sPLA 2 -IIA was monitored during infection by s.c. or intranasal route with spores of 1) a septicemic nontoxinogenic B. anthracis strain to study the role on the infection per se or 2) to study a septicemic and toxinogenic B. anthracis the effect of toxemia on the afforded protection. Furthermore, we examined the efficiency of in vivo administration of recombinant sPLA 2 -IIA to protect naturally sPLA 2 -IIA-deficient mice against B. anthracis infection. Our results showed that sPLA 2 -IIA, a natural component of the immune system, is a major actor in host defense against B. anthracis infection and suggest that recombinant sPLA 2 -IIA can be considered as a novel therapeutic agent to be used adjunct to current therapy for treating anthrax.
Materials and Methods

Mice, bacterial strains, and reagents
Human sPLA 2 -IIA female transgenic mice (C57/BL/6NTac-TgN(sPLA 2 )) and C57BL/6 wild-type congenic mice (C57BL/6NTac) were obtained from Taconic Farms. In this transgenic mouse model, the transgene fragment contains the entire human sPLA 2 -IIA gene together with a 1.6-kb region upstream of the human sPLA 2 -IIA gene, with the promoter and response elements for diverse effectors (IL-6, IFN, hepatocyte NF-3, AP1, AP2, C/EBP, and cAMP response element) (12) . Six-to 8-wk-old female C57BL/6 mice were purchased from Charles River Laboratories. The animals were housed in the Biosafety Level 2 and 3 animal facilities of the Institut Pasteur licensed by the French Ministry of Agriculture and complying with European regulations. The protocols used in this study were agreed by the Institut Pasteur Safety Committee, according to the standard procedures recommended by the Institut Pasteur Animal Care and Use Committee.
The B. anthracis strains used were the wild-type strain 9602, isolated from a fatal human case (17) and its ⌬pagA-derivative, 9602P (18); the LD 50 for both strains was Ͻ25 spores by s.c. route in OF1 mice (18) and Ͻ40 in C57BL/6 mice (this study).
Human and mouse recombinant sPLA 2 -IIA were produced in Drosophila S2 cells using the protocol previously described for human sPLA 2 -IID (19) . All the sPLA 2 preparations were checked for purity and protein integrity by SDS-PAGE analysis, MALDI-TOF mass spectrometry, and sPLA 2 enzymatic activity assays (19) . sPLA 2 
Infection experiments
Spores were prepared as previously described (20) and stored at ϩ4°C. Samples were diluted in PBS and injected either into the ear dermis (10 l), into the flank (200 l), or intranasally (30 l). Inoculum size was verified retrospectively by plating 10-fold serial dilutions on brain heart infusion (Difco) agar plates. Survival was followed for 15 days. Bacteria in organ homogenates were counted after plating 10-fold serial dilutions on brain heart infusion agar plates.
sPLA 2 assays
Broncho-alveolar lavage fluids were obtained as previously described (21) . Tissue homogenates were prepared as previously described (22, 23) . Briefly, frozen tissues were suspended in 10 volumes of a lysis buffer containing 0.25 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.5 mM PMSF, 2 g/ml leupeptin, and 2 g/ml aprotinin, and disrupted with an Ultra-Turrax T-25 (Janke and Kunkel) at 4°C. The homogenates were centrifuged for 5 min at 1,000 ϫ g, and the soluble fractions were collected and centrifuged for 20 min at 20,000 ϫ g, and the resulting supernatant was used to evaluate sPLA 2 activity. sPLA 2 activity was assayed using [ 3 H]oleate-labeled membranes of E. coli, following a modification of the method of Franson et al. (24, 25) . E. coli strain CECT 101 was grown for 6 -8 h at 37°C in the presence of 5 Ci/ml [ 3 H]oleic acid (specific activity 10 Ci/mmol) until the end of the logarithmic phase. After centrifugation at 1,800 ϫ g for 10 min at 4°C, the membranes were washed, resuspended in PBS, and autoclaved for 30 -45 min. At least 95% of the radioactivity was incorporated into the phospholipid fraction. Aliquots of plasma, broncho-alveolar lavage fluid, or tissue homogenate (10 -50 l) were incubated for 15 min with 50 l of oleatelabeled membranes (100,000 -120,000 cpm) in a buffer containing 10 mM Ca 2ϩ , and the reaction was terminated by adding 100 l of ice-cold 0.25% BSA in 100 mM Tris-HCl. After centrifugation at 2,500 ϫ g for 15 min at 4°C, the radioactivity in the supernatants was determined by liquid scintillation counting.
The identity and level of the sPLA 2 -IIA protein in tissue homogenates and biological fluids were determined by inhibition of sPLA 2 activity with LY311727 (Lilly Corporate Center) (22, 26) .
Statistical tests
Results are expressed as mean values Ϯ SEM. Student's t test and the nonparametric Wilcoxon rank sum test were used as appropriate to determine significance.
Results
Resistance of sPLA 2 -IIA transgenic mice to B. anthracis infection
Transgenic mice expressing human sPLA 2 -IIA with a C57BL/6 background and wild-type C57BL/6 control mice, that do not express endogenous sPLA 2 -IIA because of a natural frameshift mutation in the gene encoding this enzyme (27) , were inoculated into the ear with spores of the septicemic nontoxinogenic ⌬pagA strain 9602P (DL 50 Ͻ 40, a derivative (18) of the 9602 strain isolated from a fatal human case (17)). The bacterial load in various organs was quantified 16 h later (Fig. 1) . sPLA 2 -IIA transgenic mice efficiently controlled B. anthracis infection locally in the ear (only 1% of the inoculated spores remained after 16 h) and at distance in the draining lymph node, spleen, liver, and blood. Significant sPLA 2 enzymatic activity was detected in all these organs (Fig. 1) ; the enzymatic activity was fully inhibited by the sPLA 2 -IIA inhibitor LY311727 (data not shown). In sharp contrast, C57BL/6 wild-type mice did not control the infection and were already at the septicemic stage; they presented a high load of bacterial vegetative cells in all compartments. As expected, they did not express any detectable sPLA 2 -IIA activity (data not shown). In a survival assay to a lethal s.c. challenge with spores of the 9602P ⌬pagA strain, all sPLA 2 -IIA transgenic mice survived, whereas all wild-type control mice died within 4 days (Fig. 2a) . sPLA 2 -IIA transgenic mice were also protected against intranasal infection with the 9602P ⌬pagA strain, whereas wild-type control mice died within 3-4 days (Fig. 2b ). Significant sPLA 2 -IIA enzymatic activity was detected in the lung and broncho-alveolar lavage fluids of the transgenic mice (13,258 Ϯ 1,250 and 29,453 Ϯ 1,145 cpm/ml/min, respectively), but not in the C57BL/6 wild-type controls.
In addition, we tested the ability of the sPLA 2 -IIA transgenic mice to withstand a s.c. infection with the fully virulent toxinogenic and encapsulated B. anthracis strain 9602 (17) (Fig. 2c) . All sPLA 2 -IIA transgenic mice survived the infection even with a high dose challenge, whereas all wild-type control mice died within 3 days. This finding suggests that sPLA 2 -IIA effectively controlled cutaneous anthrax, decreasing the bacterial load to such an extent that not enough toxin was secreted by the residual bacteria to be lethal.
Therapeutic effect of recombinant sPLA 2 -IIA administration on B. anthracis infection
To confirm the protective role of sPLA 2 -IIA in vivo, we tested the therapeutic effect of recombinant human sPLA 2 -IIA treatment on B. anthracis infection. Recombinant sPLA 2 -IIA of two different origins (human and mouse) was injected locally (5 g) into sPLA 2 -IIA-deficient C57BL/6 mice (27) simultaneously with a s.c. challenge with spores of the septicemic nontoxinogenic ⌬pagA 9602P strain; a second recombinant sPLA 2 -IIA local injection (5 g) was given 6 h later. The B. anthracis load in the organs tested 16 h after bacterial inoculation was lower in all sPLA 2 -IIA-treated mice than in the nontreated control mice (Table I) . In a survival assay, all mice treated with sPLA 2 -IIA at 0 and 6 h after the s.c. ⌬pagA 9602P challenge survived, whereas nontreated control mice all died within 2 days (Fig. 3a) . When a single local sPLA 2 -IIA injection (5 g) was performed 6 h after s.c. ⌬pagA 9602P spore inoculation, 83% of the infected mice survived (Fig. 3b) .
We then tested whether sPLA 2 -IIA could rescue mice from a lethal inhalational challenge. sPLA 2 -IIA-deficient C57BL/6 mice were challenged by intranasal route with spores of the septicemic nontoxinogenic ⌬pagA 9602P strain and 10 g of sPLA 2 -IIA was instilled intranasally at 2, 6, and 30 h after challenge. Fifty percent of the treated mice survived the lethal challenge and the observed mortality was delayed, compared with control mice that all died within 5 days (Fig. 3c) .
We then tested the potential therapeutic effect of sPLA 2 -IIA in extremely stringent conditions, i.e., at the late stage of infection with the ⌬pagA 9602P strain, just before the onset of septicemia or when septicemia was already developing (A. Piris-Gimenez, J.-P. Corre, M. Mock, and P. L. Goossens, manuscript in preparation). sPLA 2 -IIA was injected locally at the site of infection (5 g) and i.v. (20 g) 20 h after inoculation of 9602P spores (Fig. 4) . The bacterial loads in the ear and in the draining lymph node of the sPLA 2 -IIA-treated mice were lower than those in the nontreated controls ( p Ͻ 5 ϫ 10 Ϫ3 and p ϭ 0.025, respectively). Septicemia was controlled or delayed in a significant proportion (four of seven recipients) of the sPLA 2 -IIA-treated mice ( p ϭ 0.05 for the 1-and 2.5-h time points). However, the bacterial load in the ear was higher than the injected inoculum; this suggested that encapsulated vegetative cells were still present after sPLA 2 -IIA treatment. In a modified protocol, a higher dose of sPLA 2 -IIA (10 g) was delivered locally into the ear, simultaneously with the i.v. injection (20 g ) and a survival assay was performed. No protection was observed in these conditions; however, the increase in the blood bacterial load in the first 6 h after sPLA 2 -IIA treatment was markedly reduced in the sPLA 2 -IIA-treated mice (4.8-fold Ϯ 1.8) as compared with the nontreated mice (84-fold Ϯ 31, p Ͻ 0.028). a sPLA 2 -IIA-deficient C57BL/6 mice were inoculated in the ear dermis with 3.5 log 10 spores of the 9602P strain and treated locally with recombinant sPLA 2 Finally, we tested the ability of the sPLA 2 -IIA treatment to protect mice against a s.c. infection with the fully virulent toxinogenic and encapsulated B. anthracis strain 9602 (17) (Fig. 3d) . All mice treated at 0 and 6 h with sPLA 2 -IIA, and 67% of the mice treated only at 6 h postinfection survived, whereas all wild-type control mice died within 2 days. Administration of sPLA 2 -IIA thus protected mice against wild-type toxinogenic and encapsulated B. anthracis strain expressing lethal toxin. This result shows that sPLA 2 -IIA was still able to exert its protective role even in the context of toxemia and that lethal toxin failed to interfere with the anthracidal activity of sPLA 2 -IIA.
Discussion
Anthrax curative treatment in humans relies mainly on antibiotherapy and supportive health care (28) . New therapeutic approaches are currently being developed: neutralizing mAbs against protective Ag or lethal factor (29) , chemical inhibitors of edema or lethal factor (30, 31) . In this study, we demonstrate that a natural component of the innate immune system significantly protected mice against B. anthracis infection: 1) transgenic mice expressing sPLA 2 -IIA exhibited an extremely high level of protection against cutaneous and inhalational anthrax, and 2) in vivo administration of recombinant sPLA 2 -IIA was efficient in controlling B. anthracis infection. In both cases, resistance was observed against infection with a highly virulent septicemic nontoxinogenic B. anthracis strain, thus showing that sPLA 2 -IIA controlled B. anthracis infection per se. In the s.c. murine model in which death occurs within 2 days, treatment could be postponed till 6 h after challenge. However, a single s.c. and i.v. treatment at a later stage of infection, i.e., just before the onset of septicemia or when septicemia was already developing, was inefficient in rescuing the infected mice from death. Interestingly, the local bacterial load was decreased, and septicemia could be controlled during the first hours of the sPLA 2 -IIA treatment, suggesting that increasing the dosage and number of sPLA 2 -IIA injections could help to control the infection. Protection was also observed during cutaneous and inhalational anthrax, i.e., during infection with a septicemic and toxinogenic strain, showing that sPLA 2 -IIA was still able to exert its protective role even in the context of toxemia.
Therefore, the bactericidal enzyme sPLA 2 -IIA has potential as a therapeutic agent and could be combined with the currently approved treatment of anthrax. Its action is independent of any antibiotic resistance of the B. anthracis strain causing the infection, and this is particularly valuable if the strain concerned were suspected to be multiresistant to antibiotics (as could be the case in bioterrorist threats). In support of this view, our previous studies showed that recombinant human sPLA 2 -IIA exerts its anthracidal effect at relatively low concentrations (ED 50 Х 50 ng/ml) (3) and is not toxic to mammalian host cells at much higher concentrations (up to 1 g/ml), making it suitable for therapeutic use. Indeed, at these concentrations, recombinant sPLA 2 -IIA neither released arachidonic acid, nor hydrolyzed membrane phospholipids of mammalian cells (19, 32, 33) . In addition, sPLA 2 -IIA had no toxic effect on guinea pig alveolar macrophages, U937 and HL60 monocytic cell lines, rabbit platelets, or human blood monocytes as assessed by lactate dehydrogenase release and trypan blue exclusion test (Refs. 34 and 35, and L. Touqui, unpublished observations). Furthermore, intratracheal instillation of sPLA 2 -IIA (50 g) has only a modest effect on surfactant phospholipid and respiratory functions in wild-type mice (21) .
The remarkable high selectivity of sPLA 2 -IIA action against bacterial and not mammalian cells is due, in large part, to its unique substrate preference: it is specific for anionic phospholipids such as phosphatidylglycerol (19, 36 -38) , which is the main phospholipid component of bacterial membranes. Indeed, this phospholipid is extensively hydrolyzed in sPLA 2 -IIA-treated B. anthracis bacilli (3) . Exogenously added sPLA 2 -IIA cannot hydrolyze the membrane phospholipids of mammalian cells because the outer leaflet of their plasma membrane is mainly composed by phosphatidylcholine, a very poor substrate for this enzyme (19, 32) . This is because the phospholipids are asymmetrically distributed within the plasma membrane of mammalian cells (39) .
sPLA 2 -IIA has been shown to exert in vitro a direct bactericidal effect on Gram-positive bacteria (3, 6, 8 -10) . In the sPLA2-IIAtransgenic mouse model used in this study, basal sPLA2-IIA mRNA expression has been observed in the liver, lung, skin, and kidney in the steady state (12); sPLA 2 -IIA protein has also been detected in the dermal layer of the skin and active enzyme in the serum (12) . Furthermore Laine et al. (11, 13, 14) have shown that infection of these sPLA 2 -IIA-transgenic mice by bacteria such as S. aureus and E. coli increases sPLA 2 -IIA levels in the serum and mRNA expression in the liver; cytokines such as IL-1, IL-6, and TNF-␣ also increased sPLA 2 -IIA level in the serum. We believe that, in our study, sPLA 2 -IIA acted predominantly by a direct bactericidal effect on B. anthracis, as late inoculation of the enzyme (6 and 16 h after infection) led to a decrease of the local bacterial load; at these time points, the majority of the bacteria were encapsulated and thus extracellular. Clearly this does not exclude the potential implication of an indirect effect via modifications of the immune system per se, particularly through the interaction with a receptor on certain cell types (40) . Several studies with various sPLA 2 s, including human group IIA, have shown that these sPLA 2 s can trigger iNOS induction (41), COX-2 induction (42) and IL-6, IL-8, and TNF-␣ cytokine secretion (43) , through a mechanism involving ERK1/2 (41, 44) . However, in our study, sPLA 2 -IIA was found effective even against infection with a B. anthracis strain secreting the toxins that are known to block the MAPK cascade (ERK/P38) through MEK cleavage (45, 46) ; this observation suggests a predominant direct bactericidal effect.
Administration of exogenous recombinant sPLA 2 -IIA is particularly relevant as B. anthracis lethal toxin inhibits the secretion of endogenous sPLA 2 -IIA in vitro (3), potentially decreasing the bactericidal response of the host innate immune system. The present study shows that treatment with this enzyme fully protected mice against wild-type toxinogenic B. anthracis strain expressing lethal toxin. Thus, delivery of exogenous sPLA 2 -IIA as an adjunct to therapy should thus overcome this potentially deleterious effect and complement any local and temporary deficiency of sPLA 2 -IIA, possibly a risk factor favoring the development of anthrax.
